Neurogenic Detrusor Overactivity (NDO) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Neurogenic Detrusor Overactivity (NDO) Market Outlook

Thelansis’s “Neurogenic Detrusor Overactivity (NDO) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neurogenic detrusor overactivity treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neurogenic Detrusor Overactivity (NDO) Overview

Neurogenic Detrusor Overactivity (NDO) is a dysfunction of the bladder that is commonly observed in individuals with illnesses like multiple sclerosis (MS) and spinal cord injury (SCI). Urinary incontinence (UI) and injury to the upper urinary tract can result from NDO's frequent elevation of bladder pressure. The only available treatments before adopting onabotulinumtoxin A were oral anticholinergics and surgical augmentation cystoplasty. Compared to NDO, overactive bladder (OAB) affects a broader population and is not neurogenic. Both NDO have a detrimental effect on patients' quality of life (QOL) and result in substantial costs associated with healthcare utilization. Before onabotulinumtoxinA, the OAB community also had a significant unmet demand. Behavioural therapy is the first-line treatment for overactive bladders, although long-term patient engagement is challenging. Behavioural therapy alone is not usually sufficient to meet the treatment goals of most patients; therefore, oral drugs, such as anticholinergics and, more recently, β3-adrenoceptor agonists, are frequently employed as a next step.

• According to the study, the incidence is estimated to be 30% in women and 16% for men in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: